Patel, A., Goodman, S. G., Tan, M., Suskin, N., McKelvie, R., Mathew, A. L., Lutchmedial, S., Dehghani, P., Lavoie, A. J., Huynh, T., Lavi, S., Philipp, R., Khan, R., Yan, A. T., Radhakrishnan, S., Sedlak, T., Brunner, N., Kim, H. H., Cieza, T., Kassam, S., Fordyce, C. B., Heffernan, M., Jedrzkiewicz, S., Madan, M., Ahmed, S., Barry, C., Dery, J., Bagai, A., & , (2021). contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study. Clinical cardiology, 44(6), 839–847. http://access.bl.uk/ark:/81055/vdc_100132722691.0x00004f